Literature DB >> 24814050

ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling.

Atli Thorarensen1, Mary Ellen Banker, Andrew Fensome, Jean-Baptiste Telliez, Brian Juba, Fabien Vincent, Robert M Czerwinski, Agustin Casimiro-Garcia.   

Abstract

Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry. The major focus of this effort was directed toward the identification of ATP competitive inhibitors. Although it has long been recognized that the intracellular concentration of ATP is very different from the concentrations utilized in biochemical enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function. Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors. Herein, we demonstrate utilizing the four JAK family members that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation. We evaluated a large number of JAK inhibitors in enzymatic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays. This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling. In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation. This additional data thus provides a critical piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3. Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compound's activity and selectivity in cellular contexts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24814050     DOI: 10.1021/cb5002125

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  11 in total

1.  Know your target, know your molecule.

Authors:  Mark E Bunnage; Adam M Gilbert; Lyn H Jones; Erik C Hett
Journal:  Nat Chem Biol       Date:  2015-06       Impact factor: 15.040

2.  Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.

Authors:  Steven H Spergel; Michael E Mertzman; James Kempson; Junqing Guo; Sylwia Stachura; Lauren Haque; Jonathan S Lippy; Rosemary F Zhang; Michael Galella; Sidney Pitt; Guoxiang Shen; Aberra Fura; Kathleen Gillooly; Kim W McIntyre; Vicky Tang; John Tokarski; John S Sack; Javed Khan; Percy H Carter; Joel C Barrish; Steven G Nadler; Luisa M Salter-Cid; Gary L Schieven; Stephen T Wrobleski; William J Pitts
Journal:  ACS Med Chem Lett       Date:  2019-02-13       Impact factor: 4.345

Review 3.  Non-kinase targets of protein kinase inhibitors.

Authors:  Lenka Munoz
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

4.  Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery.

Authors:  André Mateus; Laurie J Gordon; Gareth J Wayne; Helena Almqvist; Hanna Axelsson; Brinton Seashore-Ludlow; Andrea Treyer; Pär Matsson; Thomas Lundbäck; Andy West; Michael M Hann; Per Artursson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-12       Impact factor: 11.205

5.  Generation of a chemical genetic model for JAK3.

Authors:  Judit Remenyi; Rangeetha Jayaprakash Naik; Jinhua Wang; Momchil Razsolkov; Alyssa Verano; Quan Cai; Li Tan; Rachel Toth; Samantha Raggett; Carla Baillie; Ryan Traynor; C James Hastie; Nathanael S Gray; J Simon C Arthur
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

6.  Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells.

Authors:  Xiaodong Tan; Peng Liu; Yinpeng Huang; Lei Zhou; Yifan Yang; Huaitao Wang; Boqiang Yu; Xiangli Meng; Xiaobo Zhang; Feng Gao
Journal:  PLoS One       Date:  2016-03-25       Impact factor: 3.240

7.  Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

Authors:  Michael Forster; Apirat Chaikuad; Silke M Bauer; Julia Holstein; Matthew B Robers; Cesear R Corona; Matthias Gehringer; Ellen Pfaffenrot; Kamran Ghoreschi; Stefan Knapp; Stefan A Laufer
Journal:  Cell Chem Biol       Date:  2016-11-10       Impact factor: 8.116

8.  After 25 years of drug development, do we know JAK?

Authors:  Mahta Mortezavi; David A Martin; Hendrik Schulze-Koops
Journal:  RMD Open       Date:  2022-07

9.  Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.

Authors:  Martin E Dowty; Tsung H Lin; Michael I Jesson; Martin Hegen; David A Martin; Vaibhav Katkade; Sujatha Menon; Jean-Baptiste Telliez
Journal:  Pharmacol Res Perspect       Date:  2019-11-15

10.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

Authors:  Nicola E A Chessum; Swee Y Sharp; John J Caldwell; A Elisa Pasqua; Birgit Wilding; Giampiero Colombano; Ian Collins; Bugra Ozer; Meirion Richards; Martin Rowlands; Mark Stubbs; Rosemary Burke; P Craig McAndrew; Paul A Clarke; Paul Workman; Matthew D Cheeseman; Keith Jones
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.